Mouse CD3 Antibody (clone 145-2C11)

Mouse IgG2a - For in vivo use

SPECIFICATIONS

Specifications

Target

CD3

Target species

Mouse

Applications

Flow cytometry, in vivo depletion, ELISA

Antibody applications
Flow cytometry
ELISA
Species
Mouse
Isotype
mIgG2a
kappa
Clone
145-2C11
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium chloride, sodium phosphate buffer, saccharose

Preservative
Azide-free
Purity
≥ 95 %
Aggregation

< 5%

Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Sterility

0.2 µm filtration

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-mCD3-mIgG2a InvivoFit™
  • Cat code: 
    mcd3-mab10-1
  • Quantity: 
    1 mg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20 °C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

CD3 Background:

The cluster of differentiation 3 (CD3, formerly named T3) is a multimeric protein complex consisting of four polypeptides (CD3ε, CD3γ, CD3δ, and CD3ζ) that assemble as three dimers (εγ, εδ, and ζζ) [1]. The CD3 complex is a marker of T cells [1], which recognizes and participates in the elimination of infected cells and tumor cells through the interaction between the TCR on T cells and the MHC-peptide complex on antigen-presenting cells [2]. Because of its short cytoplasmic tail, the TCR lacks the ability to signal and requires non-covalent association with the CD3 [2]. Upon antigen recognition, the TCR/CD3 complex on T cells triggers downstream intracellular signaling and participates in T cell activation  [2]. The CD3ε polypeptide chain (~25 kDa) is targeted by OKT3, a monoclonal antibody that is clinically approved for the induction of immunosuppression in solid organ transplantation [3]. 

 


1. Chetty R. & Gatter K., 1994. CD3: structure, function, and role of immunostaining in clinical practice. J. Pathol. 173(4):303-307.
2. Smith-Garvin J.E. et al., 2009. T Cell Activation. Ann. Rev. Immunol. 27:591-619.
3. Norman D.J., 1995. Mechanisms of action and overview of OKT3. Therapeutics Drug Monitoring. 17:615-620.

DOCUMENTS

Documents

Anti-mCD3-mIgG2a InvivoFit™

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?